2022
Epidemiology of Hospitalized Patients with Babesiosis, United States, 2010–2016 - Volume 28, Number 2—February 2022 - Emerging Infectious Diseases journal - CDC
Bloch EM, Day JR, Krause PJ, Kjemtrup A, O’Brien S, Tobian AAR, Goel R. Epidemiology of Hospitalized Patients with Babesiosis, United States, 2010–2016 - Volume 28, Number 2—February 2022 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2022, 28: 354-362. PMID: 35076004, PMCID: PMC8798708, DOI: 10.3201/eid2802.210213.Peer-Reviewed Original ResearchConceptsNational Inpatient Sample databaseInfectious Diseases journal - CDCAnalysis of hospitalizationsHospitalized patientsAdvanced ageMortality rateHospitalizationSample databaseObservation periodEpidemiologyHigher severityPatientsBabesiosisDiagnosisUnited StatesReporting dataBabesiaAdmissionIllnessIncidenceDiseaseSeverity
2016
Transfusion-transmitted babesiosis
Levin AE, Krause PJ. Transfusion-transmitted babesiosis. Current Opinion In Hematology 2016, 23: 573-580. PMID: 27537475, PMCID: PMC5241272, DOI: 10.1097/moh.0000000000000287.Peer-Reviewed Original ResearchConceptsTransfusion-transmitted babesiosisBlood donorsB. microti antibodiesInfectious blood donorsAssociated mortality rateOptimal screening strategyTransfusion-transmitted pathogensSignificant health burdenAvailable screening toolsUnited States populationPathogen inactivation methodsMicroti antibodiesSevere illnessHealth burdenMortality rateUS FoodDrug AdministrationBabesia microtiScreening toolLaboratory screeningScreening strategyBabesiosisInactivation methodPCR assaysRecent studies
2015
Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both?
Saifee NH, Krause PJ, Wu Y. Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both? Journal Of Clinical Apheresis 2015, 31: 454-458. PMID: 26481763, DOI: 10.1002/jca.21429.Peer-Reviewed Original ResearchConceptsExchange transfusionHigh-risk populationLife-threatening illnessApparent therapeutic benefitBlood transfusionModerate diseaseClinical presentationAsymptomatic infectionSevere babesiosisSevere diseaseRisk populationsTherapeutic benefitTransfusionMortality rateIntraerythrocytic protozoan parasiteBabesia infectionDiseaseIxodes ticksProtozoan parasiteBabesiosisInfectionGenus BabesiaMost casesPatientsClindamycin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply